Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 4

Results For "Dr.-Eliav-Barr"

32 News Found

FDA accepts application for Merck’s Keytruda as adjuvant therapy for Stage IB-IIIA lung cancer
Drug Approval | June 14, 2022

FDA accepts application for Merck’s Keytruda as adjuvant therapy for Stage IB-IIIA lung cancer

Acceptance based on results from the phase 3 KEYNOTE-091 trial

USFDA seeks more analysis on Merck’s BLA for Vaxneuvance
Biotech | April 01, 2022

USFDA seeks more analysis on Merck’s BLA for Vaxneuvance

No new studies have been requested

Latest Stories

BMS’ Cobenfy sees steady start, eyes stronger growth ahead

Merck’s Capvaxive shows strong momentum amid industry vaccine decline

FDA rejects Regeneron’s Eylea HD pre-filled syringe application amid manufacturing setbacks

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
Advances in genetic testing, fertility preservation, and ART are reshaping reproductive care across India: Dr. Umesh N Jindal, Director, Jindal IVF
Advances in genetic testing, fertility preservation, and ART are reshaping reproductive care across India: Dr. Umesh N Jindal, Director, Jindal IVF
Dr. Umesh N Jindal Director, Jindal IVF
India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant
India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Dr. R. Ananthanarayanan CEO, Sajjan India

Packaging